Form 4: DarioHealth CFO Awarded 5,000 Shares

DarioHealth Corp.'s Chief Financial Officer, Chen Franco-Yehuda, was granted 5,000 shares of common stock, vesting over two years, following a recent 20-for-1 reverse stock split.

Summary

• Chen Franco-Yehuda, Chief Financial Officer of DarioHealth Corp. (DRIO), acquired 5,000 shares of common stock.
• The shares were awarded at a price of $0, indicating a restricted stock grant.
• The award will vest in two equal installments on the last day of each successive annual anniversary after the grant date of September 11, 2025, over a two-year period.
• Following this transaction, the CFO beneficially owns 30,000 shares of DarioHealth common stock.
• The reported beneficial ownership reflects the 20-for-1 reverse stock split that was effected on August 28, 2025.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key executive like the CFO is generally a positive signal, indicating management alignment and retention efforts. The vesting schedule encourages long-term commitment. The reverse stock split is a separate corporate action that provides context to the beneficial ownership number.

Positives

• The Chief Financial Officer receiving a stock award aligns management's interests with shareholders.
• The vesting schedule encourages long-term commitment from a key executive.

Future Outlook

The restricted share award will vest in two equal installments on the last day of each successive annual anniversary after the grant date over a two-year period, indicating future equity compensation for the CFO.

Industry Context

Stock awards to key executives are a common practice in the healthcare technology industry, aiming to incentivize performance and align management interests with long-term shareholder value. The reverse stock split context suggests the company is managing its share structure, which is also a common corporate action.

Stakeholder Impact

• Shareholders: Potentially positive, as it aligns the CFO's interests with long-term company performance.
• Employees: May signal stability in executive leadership.

Next Steps

• First vesting installment of 2,500 shares on September 11, 2026.
• Second vesting installment of 2,500 shares on September 11, 2027.

Key Dates

Recommendation

This Form 4 reports a routine equity award to a key executive. While it signals management alignment and retention, it does not provide new fundamental financial data or strategic shifts that would warrant a strong buy or sell recommendation based solely on this filing. It's a positive, but not a game-changing event. The context of the reverse stock split is important for understanding the share count but doesn't directly impact the recommendation from this specific transaction.

Keywords

DarioHealth, DRIO, SEC Form 4, Insider Transaction, Stock Award, Restricted Stock, CFO, Chen Franco-Yehuda, Reverse Stock Split, Beneficial Ownership